Index -
P/E -
EPS (ttm) -0.62
Insider Own 28.46%
Shs Outstand 26.04M
Perf Week -5.92%
Market Cap 6.25M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 14.91M
Perf Month -19.93%
Income -16.03M
PEG -
EPS next Q -
Inst Own 1.23%
Short Float / Ratio 0.24% / 0.87
Perf Quarter -42.78%
Sales 0.24M
P/S 26.06
EPS this Y -
Inst Trans 62.37%
Short Interest 0.04M
Perf Half Y -36.28%
Book/sh 1.36
P/B 0.22
EPS next Y -
ROA -38.86%
Target Price 2.00
Perf Year -69.91%
Cash/sh 0.94
P/C 0.32
EPS next 5Y -
ROE -41.49%
52W Range 0.29 - 0.99
Perf YTD -53.23%
Dividend -
P/FCF -
EPS past 5Y -
ROI -56.08%
52W High -69.69%
Beta 0.71
Dividend % -
Quick Ratio 10.16
Sales past 5Y 1565.19%
Gross Margin 49.49%
52W Low 4.97%
ATR 0.04
Employees 15
Current Ratio 10.16
Sales Q/Q -100.00%
Oper. Margin -6610.71%
RSI (14) 42.33
Volatility 8.87% 13.70%
Optionable No
Debt/Eq 0.01
EPS Q/Q 16.85%
Profit Margin -6659.90%
Rel Volume 0.20
Prev Close 0.33
Shortable Yes
LT Debt/Eq 0.01
Earnings -
Payout -
Avg Volume 41.13K
Price 0.30
Recom 1.00
SMA20 -7.37%
SMA50 -19.73%
SMA200 -32.94%
Volume 8,334
Change -8.87%
Nov-29-23 04:27PM
07:59AM
Nov-09-23 07:59AM
Sep-14-23 08:30AM
Sep-07-23 04:14PM
07:59AM
Loading…
Aug-01-23 07:59AM
Jul-31-23 06:00AM
Jul-20-23 08:43AM
08:40AM
Jul-13-23 09:14AM
Jun-30-23 09:28AM
Jun-29-23 02:50PM
08:29AM
Jun-06-23 04:30PM
Jun-05-23 09:00AM
07:57AM
Loading…
Jun-01-23 07:57AM
May-14-23 08:13AM
May-03-23 08:26AM
Mar-02-23 08:00AM
Feb-23-23 08:00AM
Feb-16-23 07:30AM
Jan-18-23 08:00AM
Dec-14-22 05:18PM
Dec-12-22 07:00AM
Dec-07-22 04:00PM
Dec-06-22 08:00AM
Nov-28-22 07:05PM
Nov-22-22 04:00PM
Oct-27-22 09:50AM
Oct-17-22 08:00AM
09:48AM
Loading…
Oct-14-22 09:48AM
Oct-13-22 04:00PM
Oct-12-22 08:00AM
07:31AM
Oct-10-22 09:39AM
Oct-03-22 06:03PM
09:09AM
Sep-28-22 09:00AM
Sep-20-22 08:00AM
Sep-15-22 08:00AM
Sep-12-22 11:53AM
Sep-09-22 10:32AM
Sep-06-22 09:30AM
Aug-24-22 08:00AM
Aug-18-22 08:00AM
Aug-11-22 08:00AM
07:30AM
Aug-05-22 09:00AM
Aug-02-22 07:00AM
Jul-14-22 08:00AM
Jun-23-22 09:00AM
08:00AM
Jun-22-22 08:00AM
07:30AM
Apr-14-22 04:15PM
Apr-05-22 03:57PM
Mar-30-22 04:15PM
Mar-08-22 08:00AM
07:30AM
Feb-24-22 08:00AM
Feb-09-22 08:00AM
Feb-03-22 08:00AM
Jan-26-22 08:00AM
Dec-23-21 11:35AM
07:36AM
Dec-21-21 08:00AM
Dec-01-21 08:00AM
Nov-29-21 05:45PM
Nov-24-21 08:52AM
07:34AM
Nov-23-21 11:39AM
11:31AM
08:00AM
05:02AM
Nov-17-21 08:00AM
07:30AM
Nov-11-21 08:00AM
Nov-09-21 08:00AM
Oct-27-21 11:40AM
07:45AM
07:15AM
Oct-18-21 01:37PM
11:07AM
Oct-14-21 09:13AM
07:15AM
Oct-11-21 10:08AM
08:20AM
Oct-05-21 08:37AM
Oct-04-21 08:00AM
Sep-29-21 04:30PM
Sep-20-21 12:51PM
Sep-17-21 04:05PM
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
STEINMAN LAWRENCE Director Jun 02 Buy 0.43 30,000 12,930 1,327,174 Jun 06 09:00 PM
Index -
P/E -
EPS (ttm) -14.16
Insider Own 6.83%
Shs Outstand 7.48M
Perf Week -15.90%
Market Cap 1.78M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 6.96M
Perf Month -41.95%
Income -40.45M
PEG -
EPS next Q -
Inst Own 9.66%
Short Float / Ratio 2.29% / 0.34
Perf Quarter -58.02%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -
Short Interest 0.16M
Perf Half Y -80.33%
Book/sh -0.02
P/B -
EPS next Y -
ROA -205.89%
Target Price 80.00
Perf Year -96.05%
Cash/sh 0.36
P/C 0.67
EPS next 5Y -
ROE -312.04%
52W Range 0.22 - 8.00
Perf YTD -92.98%
Dividend -
P/FCF -
EPS past 5Y -
ROI -
52W High -97.02%
Beta -
Dividend % -
Quick Ratio 0.70
Sales past 5Y 0.00%
Gross Margin -
52W Low 5.78%
ATR 0.06
Employees 5
Current Ratio 0.70
Sales Q/Q -
Oper. Margin 0.00%
RSI (14) 31.24
Volatility 19.86% 20.05%
Optionable No
Debt/Eq -
EPS Q/Q 88.23%
Profit Margin -
Rel Volume 0.64
Prev Close 0.24
Shortable Yes
LT Debt/Eq -
Earnings -
Payout -
Avg Volume 473.26K
Price 0.24
Recom 1.00
SMA20 -28.25%
SMA50 -44.84%
SMA200 -76.93%
Volume 302,090
Change -0.79%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-15-21 Initiated
Maxim Group
Buy
$11
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
08:00AM
Loading…
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
08:30AM
Loading…
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
08:00AM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
04:15PM
Loading…
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
02:26PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
08:10AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
08:00AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
STEINMAN LAWRENCE Director Jun 01 Buy 1.23 18,000 22,068 48,129 Jun 02 08:00 AM McGovern Jr. Donald A. Director May 31 Buy 1.15 10,000 11,470 30,099 Jun 01 08:00 AM McGovern Jr. Donald A. Director May 19 Buy 1.16 5,000 5,800 20,099 May 22 08:00 AM Woody James N. Chief Executive Officer May 18 Buy 1.03 40,000 41,200 41,888 May 18 04:40 PM McGovern Jr. Donald A. Director May 18 Buy 1.05 10,000 10,500 15,099 May 22 08:00 AM Marrone Pamela G Director May 18 Buy 1.06 7,082 7,507 12,469 May 19 08:45 AM Pamir Ozan CFO May 18 Buy 1.01 5,162 5,214 8,983 May 19 08:30 AM
Index RUT
P/E -
EPS (ttm) -2.65
Insider Own 24.43%
Shs Outstand 46.34M
Perf Week -10.17%
Market Cap 76.00M
Forward P/E -
EPS next Y -2.55
Insider Trans 0.02%
Shs Float 36.13M
Perf Month -3.64%
Income -124.08M
PEG -
EPS next Q -0.79
Inst Own 58.23%
Short Float / Ratio 11.41% / 10.12
Perf Quarter -32.63%
Sales 0.00M
P/S -
EPS this Y -0.82%
Inst Trans 11.61%
Short Interest 4.12M
Perf Half Y -56.44%
Book/sh 1.98
P/B 0.80
EPS next Y 7.81%
ROA -72.89%
Target Price 11.67
Perf Year -83.69%
Cash/sh 2.96
P/C 0.54
EPS next 5Y -
ROE -104.56%
52W Range 1.24 - 9.97
Perf YTD -80.73%
Dividend -
P/FCF -
EPS past 5Y -34.47%
ROI -129.31%
52W High -84.05%
Beta 0.68
Dividend % -
Quick Ratio 4.14
Sales past 5Y -71.14%
Gross Margin -
52W Low 28.23%
ATR 0.17
Employees 66
Current Ratio 4.14
Sales Q/Q -
Oper. Margin 0.00%
RSI (14) 50.22
Volatility 13.91% 10.53%
Optionable Yes
Debt/Eq 0.03
EPS Q/Q -1.40%
Profit Margin -
Rel Volume 0.67
Prev Close 1.55
Shortable Yes
LT Debt/Eq 0.01
Earnings Nov 07 AMC
Payout -
Avg Volume 407.52K
Price 1.59
Recom 1.00
SMA20 1.99%
SMA50 -0.91%
SMA200 -39.18%
Volume 272,525
Change 2.58%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-15-22 Initiated
JMP Securities
Mkt Outperform
$17
May-05-22 Downgrade
Credit Suisse
Outperform → Neutral
$35 → $5
Mar-21-22 Initiated
H.C. Wainwright
Buy
$25
Oct-15-21 Resumed
BTIG Research
Buy
$68
Jun-28-21 Initiated
ROTH Capital
Buy
$75
May-05-21 Resumed
Credit Suisse
Outperform
$68
Apr-26-21 Resumed
Credit Suisse
Outperform
$68
Jan-11-21 Initiated
JP Morgan
Overweight
$45
Jan-11-21 Initiated
Jefferies
Buy
$51
Jan-11-21 Initiated
Credit Suisse
Outperform
$49
Jan-11-21 Initiated
BTIG Research
Buy
$47
Show Previous Ratings
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
04:01PM
Loading…
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
06:48AM
Aug-02-23 11:31AM
(Thomson Reuters StreetEvents)
Aug-01-23 04:01PM
Jul-25-23 08:00AM
07:09AM
Loading…
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
(Thomson Reuters StreetEvents)
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
08:00AM
Loading…
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
(Simply Wall St.) +10.32%
Nov-08-22 08:00AM
Nov-04-22 11:15AM
09:08AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
Sep-12-22 10:08AM
Aug-18-22 06:39AM
Aug-09-22 07:25PM
04:05PM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jun-04-22 08:12AM
Jun-01-22 04:05PM
May-04-22 04:01PM
Apr-08-22 08:00AM
Mar-01-22 06:00AM
Feb-07-22 05:38PM
Jan-10-22 04:05PM
Dec-21-21 09:00AM
Dec-11-21 06:34AM
Nov-15-21 05:09PM
Oct-04-21 10:56AM
Sep-29-21 08:03AM
Sep-12-21 08:49AM
Aug-13-21 05:54PM
Jun-14-21 02:03AM
(Simply Wall St.) -19.76%
May-12-21 06:26PM
Mar-16-21 01:59AM
Dec-18-20 04:00PM
Dec-16-20 05:34PM
04:52PM
Dec-15-20 07:59PM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCBRINN SYLVIA Director Sep 08 Buy 2.54 2,000 5,080 11,125 Sep 13 06:55 PM SHORT JAY M PHD Chief Executive Officer Mar 29 Buy 2.47 40,800 100,862 1,412,387 Mar 30 07:17 PM Vasquez Christian See Remarks Mar 28 Buy 2.40 20,000 47,970 102,709 Mar 29 05:20 PM MCBRINN SYLVIA Director Dec 19 Buy 8.33 3,700 30,813 9,125 Dec 19 05:41 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite